| |
Stomach
|
Liver
|
Lung
|
|---|
|
gen
|
M/F
|
M/F
|
M/F
|
|
φ
m
b
|
11.89
|
36.90
|
13.60
|
|
D
φ
> 0
|
1311
|
231
|
506
|
|
T
1
c
|
505007.81
|
104710.40
|
452429.89
|
|
T
2
|
433148.43
|
100577.71
|
389939.77
|
|
T
3
|
453123.28
|
97629.42
|
408114.01
|
|
LRT
cat-con
d
|
21.59
|
33.84
|
19.30
|
|
β
1
e
|
0.48 (0.21, 0.81)
|
1.30 (0.68, 2.15)
|
0.96 (0.17, 2.46)
|
|
β
2
|
0.16 (-0.08, 0.46)
|
0.85 (0.25, 1.75)
|
1.84 (0.66, 4.08)
|
|
β
3
|
0.42 (0.16, 0.75)
|
1.39 (0.70, 2.34)
|
1.33 (0.38, 3.11)
|
|
Dev
|
1661.13
|
1235.38
|
1035.39
|
|
Chi-sq
|
3391.69
|
2451.56
|
3111.30
|
|
df
|
2990
|
2990
|
2990
|
| |
Colon
|
Uterus
|
All solid
|
|
gen
|
M/F
|
F
|
M/F
|
|
φ
m
b
|
20.28
|
26.91
|
43.86
|
|
D
φ
> 0
|
184
|
127
|
365
|
|
T
1
c
|
342887.98
|
128431.04
|
24656.43
|
|
T
2
|
288767.71
|
153667.68
|
21860.18
|
|
T
3
|
307331.28
|
145793.72
|
21917.87
|
|
LRT
cat-con
d
|
1.57
|
8.08
|
16.31
|
|
β
1
e
|
0.07 (-0.40, 0.95)
|
0.92 (0.19, 2.08)
|
0.13 (-0.06, 0.34)
|
|
β
2
|
0.32 (-0.31, 1.52)
|
0.28 (-0.30, 1.29)
|
0.43 (0.16, 0.74)
|
|
β
3
|
0.02 (-0.44, 0.89)
|
0.52 (-0.08, 1.48)
|
0.29 (0.06, 0.56)
|
|
Dev
|
718.42
|
630.89
|
2121.74
|
|
Chi-sq
|
3625.26
|
1038.26
|
2772.40
|
|
df
|
2990
|
1511
|
2990
|
-
a0 – 20 mSv subcohort, Excess Relative Risk ERR = β1dosecat1 + β2dosecat2 + β3dosecat3 with βi constrained by 1 + βi ≥ 0; dosecat1 = 1 if 0 < Dφ ≤ 0.025, and = 0 otherwise; dosecat2 = 1 if 0.025 < Dφ ≤ 0.05, and = 0 otherwise; dosecat3 = 1 if 0.05 < Dφ, and = 0 otherwise. The Control model is nested by β1 = β2 = β3 = 0.
-
bLatency φm is chosen from the results of the two-phase model (Table 3)
-
cAt φm, Tj is the p-y observation for which dosecatj = 1, j = 1,2,3
-
dAt φm, the likelihood ratio test LRTcat-con compares the category model with the control model (χ2 on 3 df)
-
eAt φm, βi are the fitted Maximum Likelihood Estimate parameter values, with 95%CI's
- Other definitions as in Table 3.
